http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Pyruvate Kinase M2 : A Novel Biomarker for the Early Detection of Acute Kidney Injury
Ji Hyun Cheon,Sun Young Kim,Ji Yeon Son,Ye Rim Kang,Ji Hye An,Ji Hoon Kwon,Ho Sub Song,Aree Moon,Byung Mu Lee,Hyung Sik Kim 한국독성학회 2016 Toxicological Research Vol.32 No.1
The identification of biomarkers for the early detection of acute kidney injury (AKI) is clinically important Acute kidney injury (AKI) in critically ill patients is closely associated with increased morbidity and mortality. Conventional biomarkers, such as serum creatinine (SCr) and blood urea nitrogen (BUN), are frequently used to diagnose AKI. However, these biomarkers increase only after significant structural damage has occurred. Recent efforts have focused on identification and validation of new noninvasive biomarkers for the early detection of AKI, prior to extensive structural damage. Furthermore, AKI biomarkers can provide valuable insight into the molecular mechanisms of this complex and heterogeneous disease. Our previous study suggested that pyruvate kinase M2 (PKM2), which is excreted in the urine, is a sensitive biomarker for nephrotoxicity. To appropriately and optimally utilize PKM2 as a biomarker for AKI requires its complete characterization. This review highlights the major studies that have addressed the diagnostic and prognostic predictive power of biomarkers for AKI and assesses the potential usage of PKM2 as an early biomarker for AKI. We summarize the current state of knowledge regarding the role of biomarkers and the molecular and cellular mechanisms of AKI. This review will elucidate the biological basis of specific biomarkers that will contribute to improving the early detection and diagnosis of AKI.
S-374 The Predictors of Survival of Pneumocystis Jirovecii Pneumonia in Non-HIV Patients
( Ji Soo Choi ),( Myung Jin Song ),( Bo Ra Yoon ),( Ah Young Leem ),( Joo Han Song ),( Kyung Soo Chung ),( Song Yee Kim ),( Eun Young Kim ),( Ji Ye Jung ),( Moo Suk Park ),( Young Sam Kim ),( Se Kyu K 대한내과학회 2016 대한내과학회 추계학술발표논문집 Vol.2016 No.1
Background: Pneumocystis jirovecii pneumonia (PCP) in non-HIV patients is more fatal than HIV patients, and typically present with an abrupt onset of respiratory insufficiency. To aim of this study was to evaluate the outcomes and predictors of mortality in PCP in Non-HIV critically ill patients with respiratory failure. Method: This retrospective study enrolled 81 non-HIV patients who were diagnosed and treated PCP with respiratory failure requiring the medical intensive care unit (ICU) management from January, 1, 2013 to December, 12, 2015. The patients were diagnosed through positive polymerase chain reaction (PCR, nested PCR to detection of 260bp, Thermalcycler S1000 (BIO-RAD, USA)) and typical clinical symptoms and radiological findings. PCP PCR was followed up weekly for check the negative conversion. Results: The ICU overall survival rate of PCP was 35.8% (29/81). Seventy-four patients (91.3%) required mechanical ventilation, and six patients (7.4%) required high-flow nasal oxygen treatment. In total, PCP PCR negative conversion rate is 70.5% (55/81) with a median duration of 10 (7.00-14.00) days. In univariate analysis, APACHE II score (p<0.001), renal failure requiring renal replacement therapy (p=0.04), PCP PCR negative conversion (p=0.003), and PaO2/FiO2 ratio within initial 24 hours (p<0.001) were related to mortality of PCP patients. In multivariate analysis, PCP PCR negative conversion (adjusted OR 7.424; 95% CI 1.957-28.160, p=0.003) and PaO2/FiO2 ratio within initial 24 hours (adjusted OR 0.987; 95% CI 0.979-0.996, p=0.003) were associated with prognosis of PCP in non-HIV patients with respiratory failure. Conclusions: PCP PCR negative conversion and PaO2/FiO2 ratio within initial 24 hours are prognostic factor of severe PCP in non-HIV patients with respiratory failure. Furthermore, following up PCP PCR negative conversion or not may be predictive factor to failure of initial anti-pneumocystic medication. In conclusion, early diagnosis and prompt treatment are significant to manage with PCP in non-HIV patients.
S-387 Hyperbilirubinemia in Lung Transplantation Patients
( Ji Soo Choi ),( Su Hwan Lee ),( Song Yee Kim ),( Hyo Chae Paik ),( Jin Gu Lee ),( Myung Jin Song ),( Bo Ra Yoon ),( Ah Young Leem ),( Joo Han Song ),( Kyung Soo Chung ),( Eun Young Kim ),( Ji Ye Jun 대한내과학회 2016 대한내과학회 추계학술발표논문집 Vol.2016 No.1
Background: Lung transplantation has become established treatment option for patients with end stage lung disease and steadily increased. Severe complications after lung transplantation have reported. Among them, we experienced several cases of hyperbilirubinemia. So, we reviewed for rare causes of hyperbilirubinemia after lung transplantation. Method: This is single center, retrospective cohort study of all patients who underwent lung transplantation between Apirl, 1, 2011 and January, 1, 2016. We defined hyperbilirubinemia when total bilirubin level exceeding 4mg/dL (range, 0.4-1.5 mg/L) during at least 72 hours. Results: A total 33 lung transplant recipients developed hyperbilirubinemia among 115 lung transplantation recipients in 5 years. 24 patients have common cause for hyperbilirubinemia such as drug toxicity, biliary tract stone, sepsis, bleeding and liver failure. But 9 patients have rare cause, including two patients of hemophagocytic lymphohistiocytosis (HLH), three patients of thrombotic thrombocytopenic purpura (TTP), and four patients of ischemic cholangiopathy. Interval time between transplantation and hyperbilirubinemia is approximately 2 months in HLH and ischemic cholangiopathy. On the other hand, hyperbilirubinemia with TTP occurred approximately 4 months after transplantation. Patients with HLH were treated with etoposide plus steroid or steroid alone, and patients with TTP were treated to change basiliximab instead of tacrolimus with plasmapheresis. Patients with ischemic cholangiopathy received supportive treatment. However, all 9 patients died. Conclusions: The rare cause of hyperbilirubinemia is only 7.8% (9 of 115), and all cases are associated with mortality. So, if hyperbilirubinemia after lung transplantation is developed, early evaluation and management may be necessary.
Sarcopenia and osteopenia/osteoporosis in Korean men with COPD based on KNHANES 2008-2011
( Ji An Hwang ),( Kyung Soo Jung ),( Joo Han Song ),( Song Yee Kim ),( Eun Young Kim ),( Young Seok Lee ),( Young Ae Kang ),( Moo Suk Park ),( Young Sam Kim ),( Se Kyu Kim ),( Joon Chang ),( Ji Ye Jun 대한결핵 및 호흡기학회 2015 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.120 No.-
Backgrounds: Sarcopenia and osteopenia/osteoporosis are known to be systemic features associated with COPD. We aimed to investigate the prevalence of sarcopenia and osteopenia/osteoporosis and the relationship between those in Korean men with COPD. Methods: Data on a total of 4586 male participants who underwent pulmonary function test and dual-energy X-ray absorptiometry were extracted from KNHANES between 2008 and 2011. The associations between clinical factors including lung function, BMD and appendicular skeletal muscle index (ASMI: indicator for sarcopenia) were analyzed. Results: Prevalence of sarcopenia and osteopenia/osteoporosis was higher in the 864 males with COPD than in participants with normal lung function (sarcopenia: 4.7% vs 1.8%, osteopenia/osteoporosis: 50.2%/6.5% vs 35.5%/2.9%; all P < 0.001). The proportion of patients with sarcopenia or osteoporosis increased significantly as GOLD stage progressed from stage II to III/IV (sarcopenia: 4.5% vs 21.8%; P < 0.001, osteoporosis: 5.4% vs 16.4%; P=0.006), while the change of osteopenia was not significant between the stages. Sarcopenic COPD patients had osteopenia/osteoporosis more frequently than those without [37/41 (90.2%) vs 453/823 (55.0%); P < 0.001]. ASMI was one of the independent predictors for osteopenia/osteoporosis in patients with COPD (HR 0.449; 95% CI 0.329-0.612; P < 0.001). Conclusions: Sarcopenia and osteopenia/osteoporosis were more prevalent in Korean men with COPD than those with normal lung function, and sarcopenia was closely correlated with osteopenia/osteoporosis.
Anti-Biofilm Activity of Grapefruit Seed Extract against Staphylococcus aureus and Escherichia coli
( Ye Ji Song ),( Hwan Hee Yu ),( Yeon Jin Kim ),( Na-kyoung Lee ),( Hyun-dong Paik ) 한국미생물생명공학회(구 한국산업미생물학회) 2019 Journal of microbiology and biotechnology Vol.29 No.8
Grapefruit seed extract (GSE) is a safe and effective preservative that is used widely in the food industry. However, there are few studies addressing the anti-biofilm effect of GSE. In this study, the anti-biofilm effect of GSE was investigated against biofilm-forming strains of Staphylococcus aureus and Escherichia coli. The GSE minimum inhibitory concentration (MIC) for S. aureus and E. coli were 25 μg/ml and 250 μg/ml, respectively. To investigate biofilm inhibition and degradation effect, crystal violet assay and stainless steel were used. Biofilm formation rates of four strains (S. aureus 7, S. aureus 8, E. coli ATCC 25922, and E. coli O157:H4 FRIK 125) were 55.8%, 70.2%, 55.4%, and 20.6% at 1/2 × MIC of GSE, respectively. The degradation effect of GSE on biofilms attached to stainless steel coupons was observed (≥ 1 log CFU/coupon) after exposure to concentrations above the MIC for all strains and 1/2 × MIC for S. aureus 7. In addition, the specific mechanisms of this anti-biofilm effect were investigated by evaluating hydrophobicity, auto-aggregation, exopolysaccharide (EPS) production rate, and motility. Significant changes in EPS production rate and motility were observed in both S. aureus and E. coli in the presence of GSE, while changes in hydrophobicity were observed only in E. coli. No relationship was seen between auto-aggregation and biofilm formation. Therefore, our results suggest that GSE might be used as an anti-biofilm agent that is effective against S. aureus and E. coli.
Lee, Ye-Ji,Lee, Seung-Hae,Youn, Young-So,Choi, Ji-Yeon,Song, Keung-Sub,Cho, Min-Sun,Kang, Jihee Lee Elsevier 2012 Toxicology and applied pharmacology Vol.263 No.1
<P>Mer receptor tyrosine kinase (Mer) regulates macrophage activation and promotes apoptotic cell clearance. Mer activation is regulated through proteolytic cleavage of the extracellular domain. To determine if membrane-bound Mer is cleaved during bleomycin-induced lung injury, and, if so, how preventing the cleavage of Mer enhances apoptotic cell uptake and down-regulates pulmonary immune responses. During bleomycin-induced acute lung injury in mice, membrane-bound Mer expression decreased, but production of soluble Mer and activity as well as expression of disintegrin and metalloproteinase 17 (ADAM17) were enhanced . Treatment with the ADAM inhibitor TAPI-0 restored Mer expression and diminished soluble Mer production. Furthermore, TAPI-0 increased Mer activation in alveolar macrophages and lung tissue resulting in enhanced apoptotic cell clearance in vivo and ex vivo by alveolar macrophages. Suppression of bleomycin-induced pro-inflammatory mediators, but enhancement of hepatocyte growth factor induction were seen after TAPI-0 treatment. Additional bleomycin-induced inflammatory responses reduced by TAPI-0 treatment included inflammatory cell recruitment into the lungs, levels of total protein and lactate dehydrogenase activity in bronchoalveolar lavage fluid, as well as caspase-3 and caspase-9 activity and alveolar epithelial cell apoptosis in lung tissue. Importantly, the effects of TAPI-0 on bleomycin-induced inflammation and apoptosis were reversed by coadministration of specific Mer-neutralizing antibodies. These findings suggest that restored membrane-bound Mer expression by TAPI-0 treatment may help resolve lung inflammation and apoptosis after bleomycin treatment.</P>
전산화 인지재활(RehaCom)이 정신분열증 환자의 인지기능에 미치는 효과
송예원 ( Ye Won Song ),송아영 ( A Young Song ),강수진 ( Su Jin Kang ),송지연 ( Ji Yeon Song ),최희선 ( Hu Seon Choi ),전병진 ( Byeong Jin Jeong ) 대한인지재활학회 2015 대한인지재활학회지 Vol.4 No.1
Objective: This study tried to identify the effects of computerized cognitive rehabilitation(RehaCom) through Computerized neurocognitive function test(CNT) to schizophrenic patients by conducting computerized cognitive rehabilitation(RehaCom) and to suggest the basis for cognitive rehabilitation in occupational therapy intervention of schizophrenic patients. Methods: Study subject were targeting 20 schizophrenic patients and each 10 patients were randomly allocated in experiment group and control group. Experiment period was from 2011 July 20 to September 9. Cognitive function base lines in two groups before the experiment were measured by CNT and interventions using computerized cognitive rehabilitation were conducted total of 6 times for 3 weeks, 2 times a week in experiment group, and control group participated just in the programs executed in welfare facilities. After all interventions, cognitive function improvement levels in each group were measured. In order to test average differences between two groups, independent sample t-test was conducted and to test the average differences before and after the experiment, paired t-test was conducted and subsequently, the effects of intervention on cognitive function were tested. Result: In experiment group, short-term memory(Digit span test) and executive function(card sorting test) after computerized cognitive rehabilitation showed statistically significant improvement and attention concentration ability was not statistically significant. (p<.05). Conclusion: Computerized cognitive rehabilitation was identified to be effective to schizophrenic patients in the improvement of short-term memory and executive function and therefore, computerized cognitive rehabilitation is considered to be required in future psychosocial occupational therapy.